Serum CXCL10 in Clinical and Subclinical Psoriatic Arthritis

Abstract Aim of the Work To measure CXCL10 serum level to assess its role in Psoriatic disease. Patients and Methods 45 female adult Egyptian patients with psoriatic disease were classified into 3 equal groups: PsA, subclinical PsA, and psoriasis. Full clinical assessment and laboratory investigations were done including Health Assessment Questionnaire (HAQ), Psoriasis Area Severity Index (PASI), Leeds Enthesitis Index (LEI), PsA disease activity score (DAPSA), MAdrid Sonographic Enthesitis Index (MASEI), and serum CXCL10. Results PsA patients had higher HAQ scores with high statistical significant differences compared to the other two groups. PsA patients had higher LEI compared to subclinical PsA patients with a statistical significant difference and to psoriasis patients with a high statistical significant difference. Subclinical PsA patients had higher LEI compared to psoriasis patients with a statistical significant difference. PsA patients had higher CXCL10 compared to the other 2 groups (median: 243.2 (211.2 – 415.4)). CXCL10 could detect the possibility of PsA development among subclinical PsA patients (cut-off >151 ng/l, sensitivity: 93.33% and specificity: 86.67%) and psoriasis patients (cut-off >95.5 ng/l, sensitivity, and specificity: 93.33%). CXCL10 is positively correlated with MASEI with high statistical significance in subclinical PsA and psoriasis groups and positively correlated with PASI with statistical significance in subclinical PsA group. Conclusion CXCL10 could be used to detect the possibility of PsA development among subclinical PsA and psoriasis patients. Musculoskeletal US is a screening tool to detect enthesitis in psoriasis patients.